In:
Clinical & Investigative Medicine, University of Toronto Libraries - UOTL, Vol. 32, No. 2 ( 2009-04-01), p. 117-
Abstract:
Purpose: To evaluate the effect of Haishengsu (HSS) on transplanted K562 and drug-resistant K562/ADM tumors.
Methods: Mice were inoculated subcutaneously with K562 and K562/ADM cells, respectively. Tumour-bearing animals were divided into HSS, adriamycin, combination therapy (adriamycin plus HSS) and placebo groups. The anti-tumour effect was assessed by tumour growth curve and tumour inhibitory rate (IR). Results: In animals inoculated with K562 cells, the inhibitory rates of high (1800mg/kg) and medium (900mg/kg ) dose HSS groups were 100% and 96.4%, respectively, which was higher than that in the adriamycin (88.9%) or the combination therapy groups (85.8%, P 〈 0.05). The inhibitory rate in the low-dose HSS group (53.4%) was lower than in all other groups (P 〈 0.01). In mice inoculated with K562/ADM cells, the inhibitory rates in the high, medium and low dose HSS groups were 100%, 95.9%, and 44.1%, respectively. In the adriamycin group, the inhibitory rate was 23.07%, which was lower than in the HSS group (P 〈 0.01). Pathological examination of tumour tissues from HSS-treated animals showed extensive necrosis and bleeding.
Conclusions: Haishengsu inhibits the growth of transplanted K562 tumours in mice. It is also effective in suppressing the growth of drug-resistant K562/ADM tumors in this animal model.
Type of Medium:
Online Resource
ISSN:
1488-2353
DOI:
10.25011/cim.v32i2.6029
Language:
Unknown
Publisher:
University of Toronto Libraries - UOTL
Publication Date:
2009
detail.hit.zdb_id:
2067562-8
Permalink